Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Contralateral eye comparison study in MICS and MIGS: Trabectome® vs iStent inject® (one-year results)

Poster Details

First Author: J. Gonnermann GERMANY

Co Author(s):    E. Bertelmann   M. Pahlitzsch   A. Maier-Wenzel   N. Torun   M. Klamann        

Abstract Details


To compare the safety and efficacy profile after combined micro-incision cataract surgery (MICS) and micro-invasive glaucoma surgery (MIGS) with the ab interno trabeculectomy (Trabectome®) in one eye versus two iStent® inject devices in the contralateral eye in patients with open-angle glaucoma (OAG).


Department of Ophthalmology, Charité-Universitätsmedizin Berlin


This study included 27 patients who were treated with combined MICS and ab interno trabeculectomy (group I, Trabectome®) in one eye and with combined MICS and two iStent® inject decives (group II, GTS 400) in the fellow eye. Primary outcome measures included intraocular pressure (IOP) and glaucoma medication after 6 weeks, 3, 6 and 12 months follow-up. Secondary outcome measures were number of postoperative interventions, complications and best-spectacle corrected visual acuity (BCVA).


Mean preoperative IOP was 22.3 ± 3.7 mmHg in group I and 21.3 ± 4.1 mmHg in group II (P>0.05), which decreased to 15.6 ± 3.6 mmHg for Trabectome (p<0.001) and 14.0 ± 2.3 mmHg for iStent inject (p<0.001) at 12 months after surgery without a significant difference between the two groups (p>0.05). Glaucoma medication decreased from 2.1 ± 1.1 in group I and 2.0 ± 0.9 in group II (p>0.05) before surgery to 1.4 ± 1.3 in group I and 1.3 ± 1.2 12 months postoperatively (p>0.05). No vision-threatening complications such as choroidal effusion, choroidal hemorrhage, or infection occurred. In each group trabeculectomy had to be performed in 2 eyes due to insufficient IOP lowering effect.


Ab interno trabeculectomy (Trabectome®) and iStent® inject were both effective in lowering IOP with a favourable and comparable safety profile in an intraindividual comparative study over a 12-months follow up in OAG. However, longer follow-up of these patients will be necessary to determine long-term outcomes and to evaluate significant differences.

Financial Disclosure:


Back to Poster listing